 HOLON, Israel , July 15, 2021 PRNewswire -- Compugen Ltd. Nasdaq: CGEN, a clinical-stage cancer immunotherapy company and a leader in predictive target discovery today announced that the first patient has been dosed in its Phase 1 clinical study evaluating the dual combination of COM902, the Companys potential best-in-class, high-affinity anti-TIGIT antibody and COM701, Compugens first-in-class anti-PVRIG antibody in patients with advanced malignancies who have exhausted all available standard therapies. 